Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Income from Continuing Operations: 2010-2025

Historic Income from Continuing Operations for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $30.1 million.

  • Arrowhead Pharmaceuticals' Income from Continuing Operations rose 109.30% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year increase of 104.93%. This contributed to the annual value of $30.1 million for FY2025, which is 104.94% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Income from Continuing Operations stood at $30.1 million for FY2025, which was up 104.94% from -$609.7 million recorded in FY2024.
  • Arrowhead Pharmaceuticals' Income from Continuing Operations' 5-year high stood at $30.1 million during FY2025, with a 5-year trough of -$609.7 million in FY2024.
  • Its 3-year average for Income from Continuing Operations is -$263.0 million, with a median of -$209.3 million in 2023.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Income from Continuing Operations slumped by 191.34% in 2024 and then spiked by 104.94% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Income from Continuing Operations (Yearly) stood at -$140.8 million in 2021, then dropped by 25.31% to -$176.5 million in 2022, then dropped by 18.57% to -$209.3 million in 2023, then plummeted by 191.34% to -$609.7 million in 2024, then spiked by 104.94% to $30.1 million in 2025.